Pregled bibliografske jedinice broj: 1254774
Metabolic profiling and oral galactose treatment in transgenic tg2576 mouse model of Alzheimer’s disease
Metabolic profiling and oral galactose treatment in transgenic tg2576 mouse model of Alzheimer’s disease // 9. hrvatski kongres farmakologije : zbornik sažetaka = 9th Croatian Congress of Pharmacology : Book of abstracts
Zagreb, 2019. str. 60-61 (predavanje, domaća recenzija, sažetak, znanstveni)
CROSBI ID: 1254774 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Metabolic profiling and oral galactose treatment in transgenic tg2576 mouse model of Alzheimer’s disease
Autori
Knezović, Ana ; Babić Perhoč, Ana ; Osmanović Barilar, Jelena ; Homolak, Jan ; Farkaš, Vladimir ; Bagarić, Robert ; Grünblatt, Edna ; Salković- Petrišić, Melita
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
9. hrvatski kongres farmakologije : zbornik sažetaka = 9th Croatian Congress of Pharmacology : Book of abstracts
/ - Zagreb, 2019, 60-61
Skup
9. hrvatski kongres farmakologije = 9th Croatian Congress of Pharmacology
Mjesto i datum
Zagreb, Hrvatska, 25.09.2019. - 28.09.2019
Vrsta sudjelovanja
Predavanje
Vrsta recenzije
Domaća recenzija
Ključne riječi
Alzheimer's disease ; transgenic mouse model ; metabolism
Sažetak
Introduction Alzheimer's disease (AD) is a neurodegenerative disorder associated with metabolic dysfunction in the brain. Our recent research demonstrated that chronic oral galactose treatment prevented/normalized early cognitive decline in a rat model of sporadic AD. Here we explored the effect of 2-month oral galactose treatment on cognition and brain metabolism in familial AD model, 5- and 9-month old transgenic Tg2576 mice. Materials and methods Cognition and behavior were tested by Morris Water Maze, Open Field and Elevated Plus Maze tests and metabolic status in plasma, cerebrospinal fluid and hippocampus was assessed by means of intraperitoneal glucose tolerance test and fluorodeoxyglucose PET scan. The level of insulin and glucagon-like peptide-1(GLP-1) was measured by ELISA. Results Oral galactose normalized alterations in cerebral glucose metabolism in both age groups of Tg2576 mice. However, while in cognitively unimpaired younger mice it additionally normalized plasma insulin and reduced grooming behavior, in older ones it caused further decrement in plasma insulin and worsening of glucose tolerance abnormalities without cognitive improvement. GLP-1 level was unaltered in all groups. Conclusions The results indicate that glucose/insulin- (not GLP-1) related metabolic changes precede cognitive impairment in Tg2576 mice model of familial AD with therapeutic potential of oral galactose seen on improvement of cerebral glucose metabolism only but not on cognition, underlying the differences in metabolic pathology between the two AD forms.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
POVEZANOST RADA
Projekti:
--IP-2014-09-4639 - TERAPIJSKI POTENCIJAL ORALNE GALAKTOZE U EKSPERIMENTALNOJ ALZHEIMEROVOJ BOLESTI (GALAD) (Melita Šalković, Petrišić) ( CroRIS)
IP-2018-01-8938 - Mehanizmi nutrijentom posredovanih učinaka endogenog glukagonu sličnog peptida-1 na kognitivne i metaboličke poremećaje u eksperimentalnim modelima neurodegenerativnih bolesti (NutrientGLP-1) (Šalković-Petrišić, Melita, HRZZ - 2018-01) ( CroRIS)
--KK.01.1.1.01.0007 - Znanstveni centar izvrnosti - Eksperimentalna i klinička istraživanja hipoksijsko-ishemijskog oštećenja mozga u perinatalnoj i odrasloj dobi (ZCI - NEURO) (Judaš, Miloš) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb
Profili:
Jan Homolak
(autor)
Melita Šalković-Petrišić
(autor)
Ana Babić Perhoč
(autor)
Ana Knezović
(autor)
Robert Bagarić
(autor)
Jelena Osmanović
(autor)
Vladimir Farkaš
(autor)